Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 17, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

110

Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value.

Mariluz Rojo Domingo1,2, Deondre D Do1,2, Christopher C Conlin3

  • 1Department of Bioengineering, University of California San Diego, La Jolla, California.

The Journal of Urology
|May 16, 2025
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgery in stage IIA/IIB seminoma: A "Living systematic review" and meta-analysis of prospective studies.

Indian journal of urology : IJU : journal of the Urological Society of India·2026
Same author

Androgen Deprivation Therapy (ADT) and Radiotherapy (RT) with Imaging Evaluation Longitudinally (ARIEL) trial: protocol, early results, and implications of neoadjuvant ADT for focal RT boost in prostate cancer.

medRxiv : the preprint server for health sciences·2026
Same author

Long-Term Risk of Alcohol Use Disorder in Testicular Cancer Survivors: A National Veterans Affairs Cohort Study.

Clinical genitourinary cancer·2026
Same author

Advocacy Convergence in Medicine: Analyzing Legislative Priorities and Political Action Committee Overlap Among Major Medical Societies.

Urology practice·2026
Same author

BPI26-018: Integrated Specialty Prostate Cancer Care: Outcomes From a Collaborative Clinic Model at UC San Diego Moores Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Systematic effects of patient factors and scanner/protocol factors on a Restriction Spectrum Imaging (RSI) quantitative MRI biomarker for prostate cancer.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026
Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026
Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026
Same journal

With great cost comes great responsibility: who will own the rising costs of bladder cancer care?

The Journal of urology·2026
See all related articles
Summary
This summary is machine-generated.

Restriction Spectrum Imaging restriction score (RSIrs) offers an objective biomarker for clinically significant prostate cancer (csPCa) detection. This quantitative metric performs comparably to PI-RADS and outperforms ADC, improving csPCa diagnosis without requiring radiology expertise.

Area of Science:

  • Radiology and Medical Imaging
  • Biophysics
  • Oncology

Background:

  • Prostate Imaging Reporting and Data System (PI-RADS) for clinically significant prostate cancer (csPCa) has variable predictive value.
  • Restriction Spectrum Imaging restriction score (RSIrs) is a novel, biophysics-based metric from diffusion MRI.
  • RSIrs offers potential as an objective biomarker for csPCa detection.

Purpose of the Study:

  • Evaluate the performance of RSIrs for patient-level csPCa detection in a large, heterogeneous dataset.
  • Compare RSIrs performance against apparent diffusion coefficient (ADC) and PI-RADS.
  • Assess the utility of combining RSIrs with clinical and imaging parameters for enhanced csPCa detection.

Main Methods:

  • Prostate MRI data from 1892 patients across 7 centers (January 2016 - March 2024).
Keywords:
diffusion-weighted imagingprostate MRIprostate cancer detectionquantitative biomarkerrestriction spectrum imaging

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.3K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.8K

Related Experiment Videos

Last Updated: May 17, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

110
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.3K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.8K
  • Calculation of patient-level csPCa probability using maximum RSIrs.
  • Comparison of detection performance (AUC) of RSIrs, ADC, and PI-RADS for csPCa (GG ≥ 2).
  • Multivariable regression analysis combining RSIrs with clinical factors.

    • Main Results:

    • csPCa probability increased with higher RSIrs.
    • For biopsy-naïve patients, AUCs were RSIrs=0.73, ADC=0.54, PI-RADS=0.75.
    • RSIrs significantly outperformed ADC (P < .01) and was comparable to PI-RADS (P = .31).
    • Combined RSIrs and PI-RADS outperformed either alone; the best model included RSIrs, PI-RADS, age, and PSA density.

    Conclusions:

    • RSIrs is an accurate, reliable quantitative biomarker for csPCa detection.
    • RSIrs performs better than ADC and comparably to PI-RADS.
    • RSIrs provides objective csPCa probability estimates, reducing reliance on radiologist expertise.